Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy.

Oncoimmunology · 2020 · PMC7185202 · PMID 32363120

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Despite the limited sample size (6 patients) and the sample variability, a clear trend in TH1 cytokines induction was observed both in urine and whole blood in a global analysis of cytokine secretion with a significant induction of TNFα in whole blood (Supplementary Figure 1 and 2).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.